ZA975064B - Polymorphs of donepezil hydrochloride and process for production. - Google Patents

Polymorphs of donepezil hydrochloride and process for production.

Info

Publication number
ZA975064B
ZA975064B ZA9705064A ZA975064A ZA975064B ZA 975064 B ZA975064 B ZA 975064B ZA 9705064 A ZA9705064 A ZA 9705064A ZA 975064 A ZA975064 A ZA 975064A ZA 975064 B ZA975064 B ZA 975064B
Authority
ZA
South Africa
Prior art keywords
polymorphs
donepezil hydrochloride
production
peaks
hydrochloride
Prior art date
Application number
ZA9705064A
Other languages
English (en)
Inventor
Akio Imai
Hideaki Watanabe
Takashi Kajima
Yasushi Ishihama
Akiyo Ohtsuka
Tomohide Tanaka
Yukio Narabu
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15404413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA975064(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of ZA975064B publication Critical patent/ZA975064B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
ZA9705064A 1996-06-07 1997-06-09 Polymorphs of donepezil hydrochloride and process for production. ZA975064B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14629396 1996-06-07

Publications (1)

Publication Number Publication Date
ZA975064B true ZA975064B (en) 1998-04-01

Family

ID=15404413

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9705064A ZA975064B (en) 1996-06-07 1997-06-09 Polymorphs of donepezil hydrochloride and process for production.

Country Status (16)

Country Link
US (1) US6140321A (enExample)
JP (2) JP2005015486A (enExample)
KR (1) KR100545851B1 (enExample)
CN (1) CN1312129C (enExample)
AT (1) ATE445603T1 (enExample)
AU (1) AU1153097A (enExample)
CA (1) CA2516108C (enExample)
DE (1) DE69739622D1 (enExample)
DK (1) DK1211243T3 (enExample)
ES (1) ES2330997T3 (enExample)
HU (1) HUP0900417A3 (enExample)
PT (1) PT1211243E (enExample)
SI (1) SI22888B (enExample)
UA (1) UA60307C2 (enExample)
WO (1) WO1997046526A1 (enExample)
ZA (1) ZA975064B (enExample)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513558A (ja) 1997-08-21 2001-09-04 パイ・ニュー・ゲロリュマトス・ソシエテ・アノニム アルツハイマー病を治療するためにファンキノンを使用する方法
US6274603B1 (en) 1997-09-24 2001-08-14 Mcgill University Methods for increasing ApoE levels for the treatment of neurodegenerative disease
ATE285235T1 (de) 1999-01-07 2005-01-15 Gerolymatos P N Sa Verwendung von phanquinon zur behandlung und vorbeugung von gedächtnisschwund
EP1157989B1 (en) 1999-03-03 2004-09-22 Eisai Co., Ltd. Fluorides of 4-substituted piperidine derivatives
AU2001249091A1 (en) 2000-03-03 2001-09-17 Eisai Co. Ltd. Novel methods using cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
DE60129828T2 (de) * 2000-09-25 2008-04-30 Eisai R&D Management Co., Ltd. Verfahren zur herstellung eines multiform-kristalls von donepezil hydrochlorid
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
KR20040075371A (ko) * 2002-02-07 2004-08-27 에-자이가부시기가이샤 발모 촉진제, 경피 적용 제제 및 발모 촉진 방법
EP1505078B1 (en) * 2002-05-01 2009-04-22 San-Ei Gen F.F.I., Inc. Method of modifying gum arabic
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
US20050288330A1 (en) * 2004-06-29 2005-12-29 Avinash Naidu Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride)
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2003245029A1 (en) * 2003-04-16 2004-11-04 Hetero Drugs Limited Novel crystalline forms of donepezil hydrochloride
WO2004099142A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Hydrobromide salt of benzyl-piperidylmethyl-indanone and its polymorphs
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
WO2005112946A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
US20080114173A1 (en) * 2004-07-30 2008-05-15 Mathad Vijayavitthal Thippanna Crystalline Form of Donepezil Hydrochloride
US7371906B2 (en) * 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
EP1797038B1 (en) * 2004-09-29 2012-06-13 Bayer Pharma Aktiengesellschaft Thermodynamically stable form of bay 43-9006 tosylate
US7592459B2 (en) * 2004-09-29 2009-09-22 Chemagis Ltd. Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
WO2006045512A1 (en) * 2004-10-19 2006-05-04 Krka, Tovarna Zdravil Solid pharmaceutical composition comprising donepezil hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
US20060122226A1 (en) 2004-12-08 2006-06-08 Itai Adin Crystalline forms of Donepezil base
CA2590997A1 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer`s disease
WO2006107859A2 (en) * 2005-04-04 2006-10-12 Eisai Co., Ltd. Dihydropyridine compounds for neurodegenerative diseases and dementia
JP2009502917A (ja) * 2005-07-28 2009-01-29 テイコク ファーマ ユーエスエー インコーポレーテッド ゲル化ドネペジル組成物および該組成物の製法並びに使用法
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7274339B2 (en) * 2005-09-16 2007-09-25 Smartant Telecom Co., Ltd. Dual-band multi-mode array antenna
DE102005060377A1 (de) * 2005-12-16 2007-06-21 Ratiopharm Gmbh Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung
HU227474B1 (en) * 2005-12-20 2011-07-28 Richter Gedeon Nyrt Process for industrial scale production of high purity donepezil hydrochloride polymorph i.
WO2007108011A2 (en) * 2006-03-20 2007-09-27 Ind-Swift Laboratories Limited Process for the preparation of highly pure donepezil
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP5097359B2 (ja) * 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR063319A1 (es) * 2006-10-16 2009-01-21 Medichem Sa Proceso mejorado para preparar la forma polimorfica i de clorhidrato de donepezilo (2,3-dihidro-5,6-dimetoxi-2-[[1-(fenilmetil)-4-piperidin]metil-1h-inden-1-ona)
RU2009120048A (ru) 2006-10-27 2010-12-10 Медивэйшн Ньюролоджи, Инк. (Us) Способы и комбинированные средства для лечения болезни альцгеймера
EP2081902A1 (en) * 2006-11-09 2009-07-29 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
US20100113533A1 (en) * 2006-11-14 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide
EP2131828A2 (en) * 2007-03-05 2009-12-16 Eisai R&D Management Co., Ltd. Ampa and nmda receptor antagonists for neurodegenerative diseases
EP2148673A1 (en) * 2007-04-26 2010-02-03 Eisai R&D Management Co., Ltd. Cinnamide compounds for dementia
WO2009084030A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd. Improved process for the preparation of (1-benzyl-4-(5,6,- dimethoxyind anone-2-yl)methylpiperidine) hydrochloride-form iii
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP5488956B2 (ja) * 2008-11-25 2014-05-14 株式会社Ｄｎｐファインケミカル宇都宮 （±）２−（ジメチルアミノ）−１−｛〔Ｏ−（ｍ−メトキシフェネチル）フェノキシ〕メチル｝エチル水素サクシナート塩酸塩のＩ形結晶とＩＩ形結晶の混晶の製造法
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
WO2011061591A1 (en) 2009-11-18 2011-05-26 Jubilant Life Sciences Limited Improved process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanone)-2-yl)methyl piperidine hydrochloride form-iii
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
EA037187B1 (ru) 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
CA2795559A1 (en) * 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
WO2012053016A1 (en) 2010-10-22 2012-04-26 Cadila Healthcare Limited Sustained release pharmaceutical compositions of donepezil
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN103012247B (zh) * 2013-01-18 2014-12-10 浙江东亚药业有限公司 一种盐酸多奈哌齐无水i晶型的制备方法
CN103965188A (zh) * 2013-01-29 2014-08-06 中山大学 含硒多奈哌齐类似物
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
US10357486B2 (en) 2013-08-16 2019-07-23 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
CN106397306B (zh) * 2016-10-20 2019-03-08 山东罗欣药业集团股份有限公司 一种盐酸多奈哌齐晶型化合物及其制备方法
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
HRP20231200T1 (hr) 2019-05-31 2024-01-19 Tecnimede, Sociedade Técnico-Medicinal, Sa Kombinacija fiksne doze memantina i donepezila s trenutnim otpuštanjem
EP4642432A1 (en) 2022-12-28 2025-11-05 Corium, LLC Pre-mixing method of preparing transdermal delivery system
CN120513081A (zh) 2022-12-28 2025-08-19 考里安有限责任公司 制备透皮递送系统的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi

Also Published As

Publication number Publication date
JP2009040783A (ja) 2009-02-26
CN1312129C (zh) 2007-04-25
SI22888B (sl) 2010-06-30
KR20040104707A (ko) 2004-12-10
HK1080078A1 (en) 2006-04-21
HU0900417D0 (en) 2009-08-28
HUP0900417A3 (en) 2012-12-28
DK1211243T3 (da) 2010-02-08
CA2516108C (en) 2008-12-02
KR100545851B1 (ko) 2006-01-24
ATE445603T1 (de) 2009-10-15
DE69739622D1 (de) 2009-11-26
JP2005015486A (ja) 2005-01-20
AU1153097A (en) 1998-01-05
CN1699343A (zh) 2005-11-23
UA60307C2 (uk) 2003-10-15
ES2330997T3 (es) 2009-12-18
PT1211243E (pt) 2009-11-06
SI22888A (sl) 2010-04-30
WO1997046526A1 (en) 1997-12-11
US6140321A (en) 2000-10-31
CA2516108A1 (en) 1997-12-11

Similar Documents

Publication Publication Date Title
ZA975064B (en) Polymorphs of donepezil hydrochloride and process for production.
CA2252806A1 (en) Polymorphs of donepezil hydrochloride and process for production
HUP0003141A3 (en) 4-phenylpiperidine derivatives, process for producing them and pharmaceutical compositions containing them
HUP9802762A3 (en) Diphenylmethylene piperidine derivatives, pharmaceutical compositions containing them, process for producing them and their use
AU1472995A (en) Process of producing wood charcoal in a moving bed
HRP960592A2 (en) Processes and intermediates for preparing 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine
GB8904163D0 (en) Piperazine derivative or its sait,process for producing the same and pharmaceutical composition comprising the same as active ingredient
AU690165B2 (en) Gas barrier laminate and production process thereof
AU6635990A (en) Process involving sterilization step, product having bacteriocidal activity and process for preparing the same, fumigant, fumigation method, and bacteriocidal gas composition, and process and apparatus for preparing the same
FI890245A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 1,4-disubstituoitujen piperidinyylijohdannaisten valmistamiseksi
AR242975A1 (es) Procedimiento para preparar un pigmento de dioxido de titanio recubierto.
CY2316B1 (en) Polymorphs of donepezil hydrochloride and process for production.
GB2304714B (en) New piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them
HUT74615A (en) 2,3-cyclic-condensed-1,4-dihydro-pyridine derivatives, process for producing them and pharmaceutical compositions containing the same
HU9302727D0 (en) Piperidine derivatives, process for producing them and their therapeutical use
HUP0002270A2 (hu) Donepezil-hidroklorid polimorf módosulatai, eljárás ezek előállítására, valamint e módosulatokat tartalmazó gyógyászati készítmények
HU9401188D0 (en) 3-quinolyl-substituted dihydropyridine derivatives, process for producing them and use of them in pharmaceutical compositions
HUP9800707A3 (en) Phenoxymethyl piperidine derivatives, process for producing them, and pharmaceutical compositions containing them
WO1992005152A3 (en) Process for producing polyhydroxylated piperidines and pyrrolidines and compounds thereof
AU5336990A (en) Process for generating chloric acid and chlorine dioxide
HUP0001185A3 (en) 1-phenylalkyl-1,2,3,6-tetrahydropyridines, process for producing them and pharmaceutical compositions containing them
PL303978A1 (en) Novel derivatives of piperidine and piperazine, method of obtaining them as well as pharmaceutical preparation and method of obtaining same
HUT68249A (en) 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor and pharmaceutical composition containing it and process for producing thereof
NO941134D0 (no) 1,2,5,6-tetrahydropyridin-derivat, fremgangsmåte for dets fremstilling, og dets terapeutiske anvendelser
BR1100141A (pt) Composto de 1-benzil-4-[(5,6-dimetoxi-1-indanona)-2-il]metilpiperidin a, agente inibidor de acetilcolinesterase, agente para prevenir e tratar vários tipos de demências senis e processo para produzir 1-benzil-4-[(5,6-dimetoxi-1-indanona)-2-il]metilpiperidin a